NCT04019080

Brief Summary

The objective of the current research project is, by using high quality Swedish registry data, to evaluate use, tolerance and effect of anti-fibrotic drugs in IPF-patients. Secondary study objectives are to determine the clinical profile, determinants of treatment adherence, long-term safety and to describe the patient journey from the first sign of disease to end of treatment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2019

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 11, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 15, 2019

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

July 15, 2019

Status Verified

July 1, 2019

Enrollment Period

2.9 years

First QC Date

July 11, 2019

Last Update Submit

July 11, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Anti-fibrotic drugs among the patients recorded in the Swedish IPF-registry

    The use of anti-fibrostic drugs

    2014-2020

Interventions

The real-Life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in Sweden

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed with idiopathic pulmonary fibrosis included in the Swedish IPF-registry

You may qualify if:

  • All subjects included in the Swedish IPF-registry

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Karolinska University Hospital

Stockholm, Sweden

RECRUITING

MeSH Terms

Conditions

Idiopathic Pulmonary Fibrosis

Condition Hierarchy (Ancestors)

Pulmonary FibrosisLung Diseases, InterstitialLung DiseasesRespiratory Tract Diseases

Central Study Contacts

Sköld, Prof

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor, Senior consultant

Study Record Dates

First Submitted

July 11, 2019

First Posted

July 15, 2019

Study Start

January 1, 2019

Primary Completion

December 1, 2021

Study Completion

December 1, 2021

Last Updated

July 15, 2019

Record last verified: 2019-07

Locations